Essential roles for Pot1b in HSC self-renewal and survival

Blood

Volumn 118, Issue 23, 2011, Pages 6068-6077

  Wang, Yang ^a   Shen, Mei Feng ^a   Chang, Sandy ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN P53; PROTEIN POT1B; TELOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE DELETION; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; LIFESPAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 82955207699     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-361527     Document Type: Article

References (50)

1. Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475-1485.
2. Greider CW. Telomere length regulation. Annu Rev Biochem. 1996;65:337-365. (Pubitemid 26250613)
3. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349): 349-352. (Pubitemid 28063364)
4. Vaziri H, Dragowska W, Allsopp RC, et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A. 1994;91(21):9857-9860. (Pubitemid 24311907)
5. Rufer N, Dragowska W, Thornbury G, et al. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 1998;16(8):743-747. (Pubitemid 28363755)
6. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001;413(6854):432-435. (Pubitemid 32928599)
7. Marrone A, Walne A, Tamary H, et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood. 2007; 110(13):4198-4205. (Pubitemid 351377783)
8. Vulliamy T, Marrone A, Szydlo R, et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36(5):447-449. (Pubitemid 38620026)
9. Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102(44):15960-15964. (Pubitemid 41552850)
10. Cawthon RM, Smith KR, O'Brien E, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393-395. (Pubitemid 36164975)
11. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91(1):25-34. (Pubitemid 27431310)
12. Lee HW, Blasco MA, Gottlieb GJ, et al. Essential role of mouse telomerase in highly proliferative organs. Nature. 1998;392(6676):569-574. (Pubitemid 28207706)
13. Samper E, Flores JM, Blasco MA. Restoration of telomerase activity rescues chromosomal instability and premature aging in Terc-/- mice with short telomeres. EMBO Rep. 2001;2(9):800-807. (Pubitemid 32982748)
14. Jaskelioff M, Muller FL, Paik JH, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature. 2011; 469(7328):102-106.
15. Chan SS, Chang S. Defending the end zone: studying the players involved in protecting chromosome ends. FEBS Lett. 2010;584(17):3773- 3778.
16. Hockemeyer D, Daniels J-P, Takai H, et al. Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell. 2006;126(1):63-77.
17. He H, Multani AS, Cosme-Blanco W, et al. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J. 2006;25(21):5180-5190. (Pubitemid 44658535)
18. Wu L, Multani AS, He H, et al. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell. 2006;126(1):49-62.
19. Hockemeyer D, Palm W, Wang RC, et al. Engineered telomere degradation models dyskeratosis congenita. Genes Dev. 2008;22(13):1773- 1785.
20. He H, Wang Y, Guo X, et al. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol Cell Biol. 2009;29(1):229-240.
21. Savage SA, Giri N, Baerlocher GM, et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Human Genet. 2008;82(2):501-509.
22. Walne AJ, Vulliamy T, Beswick R, et al. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood. 2008;112(9):3594- 3600.
23. Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet. 2004;36(1):63-68. (Pubitemid 38056209)
24. Hawkins AL, Jones RJ, Zehnbauer BA, et al. Fluorescence in situ hybridization to determine engraftment status after murine bone marrow transplant. Cancer Genet Cytogenet. 1992;64(2):145- 148.
25. Guo X, Deng Y, Lin Y, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J. 2007;26(22):4709-4719. (Pubitemid 350126798)
26. Essers MA, Offner S, BlancoBose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
27. Randall TD, Weissman IL. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood. 1997;89(10):3596-3606. (Pubitemid 27227082)
28. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8(6):450-458. (Pubitemid 351744962)
29. Rudolph KL, Chang S, Lee H-W, et al. Longevity, stress response, and cancer in aging telomerasedeficient mice. Cell. 1999;96(5):701-712. (Pubitemid 29122812)
30. Cosme-Blanco W, Shen MF, Lazar AJ, et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 2007;8(5):497- 503.
31. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003;13(17):1549-1556. (Pubitemid 37078413)
32. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere- initiated senescence. Nature. 2003;426(6963): 194-198. (Pubitemid 37442589)
33. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science. 1997; 277(5327):831-834. (Pubitemid 27366737)
34. Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem. 2001; 268(10):2784-2791. (Pubitemid 32862960)
35. Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22(16): 4212-4222. (Pubitemid 37021749)
36. Hills M, Lansdorp PM. Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Ann N Y Acad Sci. 2009;1176: 178-190.
37. Ohyashiki JH, Iwama H, Yahata N, et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res. 1999;5(5):1155-1160. (Pubitemid 29233232)
38. Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U SA. 2009;106(4):1187-1192.
39. Kirwan M, Vulliamy T, Marrone A, et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat. 2009;30(11):1567-1573.
40. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood. 2008; 111(9):4446-4455.
41. Brümmendorf TH, Maciejewski JP, Mak J, et al. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97(4): 895-900. (Pubitemid 32154271)
42. Wang F, Podell ER, Zaug AJ, et al. The POT1- TPP1 telomere complex is a telomerase processivity factor. Nature. 2007;445(7127):506-510. (Pubitemid 46197626)
43. Xin H, Liu D, Wan M, et al. TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature. 2007;445(7127):559- 562.
44. Yang D, He Q, Kim H, et al. TIN2 dyskeratosis congenital missense mutants are defective in association with telomerase. J Biol Chem. 2011; 286(26):23022-23030.
45. Abreu E, Aritonovska E, Reichenbach P, et al. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol Cell Biol. 2010;30(12): 2971-2982.
46. Rossi DJ, Bryder D, Seita J, et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature. 2007; 447(7145):725-729. (Pubitemid 46889729)
47. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature. 2007;448(7157):1068- 1071.
48. Flynn RL, Centore RC, O'Sullivan RJ, et al. TERRA and hnRNPA1 orchestrate an RPA-to- POT1 switch on telomeric single-stranded DNA. Nature. 2011;471(7339):532-536.
49. Rai R, Zheng H, He H, et al. The function of classical and alternative non-homologous end-joining pathways in the fusion of dysfunctional telomeres. EMBO J. 2010;29(15):2598-2610.
50. Palm W, Hockemeyer D, Kibe T, et al. Functional dissection of human and mouse POT1 proteins. Mol Cell Biol. 2009;29(2):471-482.